

World Journal of *Gastroenterology*

World J Gastroenterol 2017 April 21; 23(15): 2635-2818



**EDITORIAL**

- 2635 Dietary compliance in celiac disease

Freeman HJ

- 2640 Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?

Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S

REVIEW

- 2651 Hepatitis B virus infection and alcohol consumption

Iida-Ueno A, Enomoto M, Tamori A, Kawada N

- 2660 Endoscopic management of pancreatic fluid collections-revisited

Nabi Z, Basha J, Reddy DN

ORIGINAL ARTICLE**Basic Study**

- 2673 Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis

Bartczak A, Zhang J, Adeyi O, Amir A, Grant D, Gorczynski R, Selzner N, Chruscinski A, Levy GA

- 2685 Changes in human hepatic metabolism in steatosis and cirrhosis

Schofield Z, Reed MAC, Newsome PN, Adams DH, Günther UL, Lalor PF

- 2696 Effect of *Lactobacillus rhamnosus* HN001 and *Bifidobacterium longum* BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study

Toscano M, De Grandi R, Stronati L, De Vecchi E, Drago L

- 2705 Effects of Hwangryunhaedok-tang on gastrointestinal motility function in mice

Kim H, Kim I, Lee MC, Kim HJ, Lee GS, Kim H, Kim BJ

- 2716 Role of $\Delta 133p53$ isoform in NF- κ B inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells

Zhang HM, Sang XG, Wang YZ, Cui C, Zhang L, Ji WS

Retrospective Cohort Study

- 2723 Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M

Retrospective Study

- 2731 Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain)

Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, Gutierrez-Ibarluzea I

- 2743 Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening

Sekiguchi M, Terauchi T, Kakugawa Y, Shimada N, Saito Y, Matsuda T

- 2750 Association of obesity with
- Helicobacter pylori*
- infection: A retrospective study

Xu MY, Liu L, Yuan BS, Yin J, Lu QB

- 2757 Outcomes and prognostic factors of patients with stage IB and II A pancreatic cancer according to the 8
- th
- edition American Joint Committee on Cancer criteria

Li Y, Tang CG, Zhao Y, Cao WY, Qu GF

Clinical Trials Study

- 2763 Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma

Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI

- 2771 Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease

Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY

Observational Study

- 2785 Age-related impairment of esophagogastric junction relaxation and bolus flow time

Cock C, Besanko LK, Burgstad CM, Thompson A, Kritas S, Heddle R, Fraser RJL, Omari TI

- 2795 Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop

Liu YM, Yang XJ

- 2802 Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients

Cheng JL, Wang XL, Yang SG, Zhao H, Wu JJ, Li LJ

CASE REPORT

- 2811 One step minilaparotomy-assisted transmesenteric portal vein recanalization combined with transjugular intrahepatic portosystemic shunt placement: A novel surgical proposal in pediatrics

Pelizzo G, Quaretti P, Moramarco LP, Corti R, Maestri M, Iacob G, Calcaterra V

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Oya Yucel, PhD, Associate Professor, Pediatric Department, Baskent University, Istanbul Teaching and Medical Research Hospital, Istanbul 34662, Turkey

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports[®] released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Fen-Fen Zhang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
April 21, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>



Retrospective Study

Outcomes and prognostic factors of patients with stage I B and II A pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria

Yang Li, Chuan-Gang Tang, Yu Zhao, Wu-You Cao, Guo-Feng Qu

Yang Li, Department of Hepatobiliary Surgery, Organ Transplantation Center, Tianjin First Center Hospital, Tianjin 300192, China

Chuan-Gang Tang, Guo-Feng Qu, Department of Breast Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou 221009, Jiangsu Province, China

Yu Zhao, Department of Surgery, Tianjin Second People's Hospital, Tianjin 300192, China

Wu-You Cao, School of Medicine, Southeast University, Nanjing 210009, Jiangsu Province, China

Author contributions: Tang CG, Cao WY and Qu GF designed the research and critically revised the manuscript for important intellectual content; Li Y and Zhao Y performed the research, analyzed the data and wrote the paper.

Institutional review board statement: The study has been approved by the Bioethics Committee of the Affiliated Xuzhou Hospital of Medical College of Southeast University, China.

Informed consent statement: All patients from the SEER database have agreed to participate in scientific research.

Conflict-of-interest statement: All authors declare no competing financial interests.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Dr. Guo-Feng Qu, Department of Breast Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, No.199 South Jiefang Road, Xuzhou 221009, Jiangsu Province, China. lissier_126@sina.com
Telephone: +86-516-83956162

Received: December 15, 2016

Peer-review started: December 18, 2016

First decision: January 19, 2017

Revised: February 9, 2017

Accepted: March 15, 2017

Article in press: March 15, 2017

Published online: April 21, 2017

Abstract

AIM

To evaluate the changes in the 8th edition American Joint Committee on Cancer (AJCC) for defining stage I B and II A pancreatic cancer and identify their prognostic factors.

METHODS

Pancreatic cancer patients were selected from the Surveillance Epidemiology and End Results database (1973-2013). The enrolled patients were divided into I B and II A groups based on tumor size according to the 8th edition AJCC criteria. Clinical characteristics, including age, gender, race, tumor size, primary site, and grade were summarized. Univariate and multivariate analyses were performed to explore the prognostic factors of the I B and II A stages of pancreatic cancer under new criteria.

RESULTS

A total of 1349 pancreatic cancer patients were included. More patients had stage I B rather than stage II A. Stage I B tumors (54.85%) were mainly

located in the head of the pancreas, while stage II A tumors were more often located in the tail and head of the pancreas (35.21% and 31.75%, respectively). The survival time of stage I B and II A patients had no significant difference. Univariate and multivariate analyses indicated that the prognostic factors of survival for stage I B and II A patients were different. For stage I B patients, age and primary site were the independent prognostic factors; for stage II A patients, age and grade were the independent prognostic factors. The risk of death was lower among patients aged ≤ 65 years than those aged > 65 years.

CONCLUSION

The prognostic factors for stage I B and II A patients are different, but age is the independent prognostic factor for all patients. The survival time of stage I B and II A patients has no significant difference.

Key words: Pancreatic cancer; Prognostic factor; 8th American Joint Committee on Cancer; TNM; Tumor size

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The 8th edition American Joint Committee on Cancer TNM criteria for pancreatic cancer emphasize the tumor size cutoff point of 4 cm for the first time. Thus we used the Surveillance Epidemiology and End Results database, a population-based database, to evaluate the new changes in pancreatic cancer staging and the prognostic factors of stage I B and II A pancreatic cancer.

Li Y, Tang CG, Zhao Y, Cao WY, Qu GF. Outcomes and prognostic factors of patients with stage I B and II A pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria. *World J Gastroenterol* 2017; 23(15): 2757-2762 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i15/2757.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i15.2757>

INTRODUCTION

Pancreatic cancer is an aggressive and devastating disease, which is characterized by invasiveness, rapid progression, and profound resistance to treatment^[1-3]. The incidence of pancreatic cancer in the United States and western Europe is 10/100000 per year and almost approaches mortality^[4]. The overall survival rate at 5 years is less than 5%^[5,6]. Surgical resection is still the only treatment providing prolonged survival; however, even after a curative resection, the 5-year survival rate remains low^[7].

Tumor size is the basis of cancer staging, which is one of the strongest prognostic factors in various cancers, including pancreatic cancer^[8-10]. Compared with the 6th and 7th edition of the American Joint

Committee on Cancer (AJCC) system for defining stage I B pancreatic cancer (IB: tumor diameter > 2 cm, no regional lymph node metastasis, no distant metastasis)^[11], the 8th edition AJCC criteria emphasize the cutoff point of 4 cm (IB: tumor diameter > 2 but ≤ 4 cm; II A: tumor diameter > 4 cm, both with no regional lymph node metastasis and no distant metastasis)^[12,13]. Clinically, the size and location of pancreatic tumor determine the type of surgical resection^[14-16], which suggests the important role of tumor size and location. Therefore, the aim of this study was to evaluate the changes in the AJCC system for defining stage I B and II A pancreatic cancer and identify their prognostic factors.

MATERIALS AND METHODS

Patients

The Surveillance Epidemiology and End Results (SEER) database (1973-2013) was used for the study. The National Cancer Institute's SEER*Stat software (Version 8.2.0) was used to identify patients. All patients underwent surgical treatment and had a pathologically confirmed diagnosis of stage I B pancreatic tumor according to the 6th and 7th edition of the AJCC criteria. Patients with unknown tumor size were excluded. Demographics, including age, gender, and race, were retrieved. Tumor variables included location of the primary tumor, tumor size, and grade. Survival data were extracted at 1 mo intervals for a follow-up period between 1 mo and 110 mo.

Statistical analysis

The enrolled patients were divided into two groups based on tumor size according to the 8th edition AJCC criteria (IB: tumor diameter > 2 but ≤ 4 cm, II A: tumor diameter > 4 cm). The independent *t*-test and the χ^2 test were used for the difference analysis between the two groups. Univariate analysis with the log-rank test and multivariate analysis with the Cox proportional hazards regression model were performed to explore the difference in prognostic factors between the two groups, with *P* values < 0.05 considered statistically significant. All analyses were performed using SPSS software, version 13.0 for Windows.

RESULTS

A total of 1349 pancreatic cancer patients were selected from the SEER database. The age of the patients ranged from 18 to 90 years, with a median age of 65 years. There were 626 male patients and 723 female patients. The median tumor diameter was 43.4 mm (range, 21-540 mm). The pathological stage was classified as I B in 886 patients and II A in 463 patients, according to the AJCC 8th criteria. The total median survival of these patients was 62 mo, and their 1-, 3-, and 5-year survival rates were 83.8%, 58.9%, and 50.6%, respectively. The patients' clinical characteristics

Table 1 Clinical characteristics of the entire patient cohort¹ *n* (%)

Characteristic	Entire cohort	Stage I B	Stage II A	<i>P</i> value
Number of patients	1349	886	463	
Age (yr), median (range)	65 (18-90)	65 (18-90)	63 (18-90)	0.000
Tumor size (mm), mean (range)	43.4 (21-540)	29.5 (21-40)	70.0 (41-540)	0.000
Gender				
Male	626 (46.40)	405 (45.71)	221 (47.73)	0.480
Female	723 (53.60)	481 (54.29)	242 (52.27)	
Primary site				
Head	633 (46.9)	486 (54.85)	147 (31.75)	0.000
Body	165 (12.23)	103 (11.6)	62 (13.39)	
Tail	350 (25.95)	186 (20.99)	164 (35.21)	
Other	201 (14.90)	111 (12.53)	90 (19.44)	
Grade				
I	348 (25.80)	221 (24.94)	127 (27.43)	0.006
II	484 (35.88)	335 (37.81)	149 (32.18)	
III	230 (17.05)	164 (18.52)	66 (14.25)	
IV	17 (1.26)	10 (1.13)	7 (1.51)	
Unknown	270 (20.01)	156 (17.61)	114 (24.62)	
Race				
White	1060 (78.58)	694 (78.33)	366 (79.05)	0.760
Other	289 (21.42)	192 (21.67)	97 (20.95)	

¹Factors were compared by independent *t* test and χ^2 test for continuous and categorical variables, respectively.

Table 2 Prognostic significance for overall survival by univariate analysis of variables for stage I B and II A patients¹

Variable	Stage I B		Stage II A	
	<i>n</i>	Log-rank	<i>n</i>	Log-rank
Age (yr)				
≤ 65	444	0.000	270	0.000
> 65	442		193	
Gender				
Male	405	0.162	221	0.002
Female	481		242	
Tumor size (mm)				
21-30	584	0.258		
31-40	302			
41-70			332	0.013
> 70			131	
Primary site				
Head	486	0.000	147	0.004
Body	103		62	
Tail	186		164	
Other	111		90	
Grade				
I	221	0.000	127	0.000
II	335		149	
III	164		66	
IV	10		7	
Unknown	156		114	
Race				
White	694	0.148	366	0.685
Other	192		97	

¹Univariate analysis was done by Kaplan-Meier method.

are presented in Table 1.

Under the new criteria, the median tumor diameter of stage I B patients was 29.5 mm, while the median tumor diameter of stage II A patients was 70.0 mm. The primary site of 54.85% of stage I B tumors was the head of the pancreas, while the primary site of stage II

A tumors was mainly the tail and head of the pancreas (35.21% and 31.75%, respectively). Among both stage I B and II A patients, the majority (approximately 60%) were in grade I and II.

Univariate survival analysis of clinical characteristics was evaluated with a log-rank test (Table 2). Age, grade and primary site were significantly associated with the overall survival of stage I B patients ($P < 0.05$), while gender and race showed no significant association with survival ($P > 0.05$). For stage II A patients, age, gender, grade, and primary site were significantly associated with overall survival ($P < 0.05$), but race showed no significant association with survival ($P > 0.05$). Multivariate analyses for stage I B and II A patients were performed with the Cox regression model (Table 3). The results indicated that for stage I B patients, age and primary site were the independent prognostic factors; for stage II A patients, age and grade were the independent prognostic factors ($P < 0.05$). Overall, the survival time of stage I B and II A patients had no significant difference (Figure 1A); whereas, for both stage I B and II A, the risk of death was lower for patients aged ≤ 65 years than those aged > 65 years (Figure 1B).

DISCUSSION

As one of the most lethal human cancers, pancreatic cancer staging is of important significance clinically. Regardless of how the AJCC definitions of pancreatic cancer staging change, the diameter of the tumor has been shown to be a strong predictor of prognosis. The current cutoff points of > 2 but ≤ 4 and > 4 cm have been proposed to be the sole factor governing the I B and II A stages in pancreatic cancer. However, the




Figure 1 Kaplan-Meier analysis of overall survival. A: Among 1349 patients, the survival time of stage I B and II A patients had no significant difference ($P > 0.05$); B: For both stage I B and II A, death risk was lower in patients aged ≤ 65 yr than those aged > 65 yr.

Table 3 Prognostic significance for overall survival by multivariate analysis of variables for stage I B and II A patients¹

Variable	Stage I B			Stage II A		
	RR	95%CI	P value	RR	95%CI	P value
Age	1.037	1.025-1.049	0.000	1.045	1.029-1.062	0.000
Gender (male vs female)	1.128	0.887-1.434	0.327	1.235	0.852-1.790	0.265
Tumor size	1.018	0.996-1.039	0.000	1.003	0.999-1.008	0.173
Primary site (head vs body-tail)	1.734	1.311-2.294	0.000	1.197	0.825-1.736	0.345
Grade (I + II vs III + IV)	0.570	0.443-0.734	0.104	0.490	0.333-0.721	0.000

¹Multivariate analysis was done with Cox proportional hazard regression model.

results from the current study suggest that they are not statistically sound, since the patients with stage I B and II A cancer had similar outcomes ($P > 0.05$). The findings reported by Burcu^[17] contradicts our findings. Thus, further studies or more clinical data are required to evaluate the cutoff point of 4 cm tumor diameter.

In addition, moving to a different staging system has implications and comes with its challenges, such as hampered comparison with earlier data. In this study, all patients were pathologically diagnosed with stage I B pancreatic tumor according to the 6th and 7th edition AJCC criteria, which means the data were discrete over past decades. Therefore, further work needs to be done to evaluate the quality of the data.

Pancreatic cancer can be divided into head and body/tail cancers according to the anatomy. In this study, we found that stage I B tumors were mainly located in the head of the pancreas, while stage II A tumors were more often located in both the tail and head of the pancreas (35.21% and 31.75%, respectively). Generally, pancreatic development begins with the formation of a ventral and a dorsal bud, which become the ventral head (lower head and uncinate process) and dorsal pancreas (upper head, body, and tail), respectively. This difference in ontogeny leads to significant differences in cell composition, blood supply, lymphatic and venous backflow, and innervations between the head and body/tail of the pancreas^[18]. For instance, the number of islets of Langerhans is greater in the body and tail. There have been some reports

showing the significance of tumor location in terms of the prognosis of pancreatic tumor. For example, in pancreatic serous cystic neoplasms and intraductal papillary mucinous neoplasms, tumor location in the head of the pancreas was independently associated with local invasiveness and recurrence^[19,20], while in pancreatic neuroendocrine tumors, tumors located at the body/tail of the pancreas were more likely to be associated with shorter progression-free survival^[21]. Our analysis indicates that tumor location has a correlation with the prognosis in stage I B pancreatic cancer patients.

Prognostic factors combining clinical and laboratory variables with physician's estimates have been developed in recent years^[22]. However, in this study, we just selected patients from the SEER database to analyze the prognostic factors. It is necessary for us to include more variables using our own patient database to verify the new TNM staging system.

In conclusion, our analysis demonstrates that more patients tend to be stage I B rather than stage II A when they are diagnosed. Overall survival is mainly associated with age and primary site for stage I B patients, while for stage II A patients, age and grade are the independent prognostic factors. The common independent prognostic factor for both patient groups is age. However, the survival time of stage I B and II A patients has no significant difference. The results suggest that the new AJCC criteria need further evaluation.

COMMENTS

Background

Compared with the 6th and 7th edition American Joint Committee on Cancer (AJCC) system for TNM staging of pancreatic cancer, the 8th edition AJCC criteria emphasize the cutoff point of 4 cm.

Research frontiers

AJCC TNM staging of pancreatic cancer has just been updated to the 8th edition. The aim of our study was to evaluate the changes in the AJCC system for defining stage I B and II A pancreatic cancer - the cutoff point of 4 cm and to identify their prognostic factors.

Innovations and breakthroughs

The prognostic factors for stage I B and II A patients are different, and age is the common factor. But the survival time of stage I B and II A patients has no significant difference.

Applications

The new AJCC criteria need further evaluation.

Peer-review

This is a large retrospective study of patients undergoing resection for pancreatic cancer. The authors have chosen to look at tumor size as an absolute value for determining survival in patients having resection for pancreatic cancer. The manuscript is succinct and reasonably well written. The figures and tables are appropriate.

REFERENCES

- 1 Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer* 2002; **2**: 897-909 [PMID: 12459728 DOI: 10.1038/nrc949]
- 2 Hidalgo M. Pancreatic cancer. *N Engl J Med* 2010; **362**: 1605-1617 [PMID: 20427809 DOI: 10.1056/NEJMra0901557]
- 3 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. *Lancet* 2004; **363**: 1049-1057 [PMID: 15051286 DOI: 10.1016/S0140-6736(04)15841-8]
- 4 Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. *Eur J Cancer* 2004; **40**: 549-558 [PMID: 14962722 DOI: 10.1016/j.ejca.2003.10.026]
- 5 Freilove R, Walling AD. Pancreatic cancer: diagnosis and management. *Am Fam Physician* 2006; **73**: 485-492 [PMID: 16477897]
- 6 Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: the actual 5-year survivors. *J Gastrointest Surg* 2008; **12**: 701-706 [PMID: 18027062 DOI: 10.1007/s11605-007-0384-8]
- 7 Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? *Langenbecks Arch Surg* 2005; **390**: 94-103 [PMID: 15578211 DOI: 10.1007/s00423-004-0476-9]
- 8 Winter JM, Jiang W, Basturk O, Mino-Kenudson M, Fong ZV, Tan WP, Lavu H, Vollmer CM, Furth EE, Haviland D, Klimstra DS, Jarnagin WR, Lillmoen KD, Yeo CJ, Fernandez-Del Castillo C, Allen PJ. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤ 20 -mm Invasive Component): A Multi-institutional Analysis. *Ann Surg* 2016; **263**: 793-801 [PMID: 26135696 DOI: 10.1097/sla.0000000000001319]
- 9 Rohan VS, Hsu JT, Liu KH, Yeh CN, Yeh TS, Jan YY, Hwang TL. Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas. *J Gastrointest Cancer* 2013; **44**: 89-93 [PMID: 23076797 DOI: 10.1007/s12029-012-9448-4]
- 10 Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H. Prognostic factors after resection of pancreatic cancer. *World J Surg* 2009; **33**: 104-110 [PMID: 19011933 DOI: 10.1007/s00268-008-9807-2]
- 11 Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. *Cancer* 2007; **110**: 738-744 [PMID: 17580363 DOI: 10.1002/cncr.22852]
- 12 Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK, Woo SM, Joo YE, Jeong S, Lee SO, Park BK, Cheon YK, Han J, Kim TN, Lee JK, Moon SH, Kim H, Park ET, Hwang JC, Kim TH, Jeon TJ, Cho CM, Choi HS, Lee WJ. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. *Pancreas* 2016; **45**: 941-946 [PMID: 26765964 DOI: 10.1097/mpa.0000000000000586]
- 13 Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. *Am J Surg Pathol* 2016; **40**: 1653-1660 [PMID: 27631521 DOI: 10.1097/PAS.0000000000000738]
- 14 Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. *Ann Surg Oncol* 2006; **13**: 1035-1046 [PMID: 16865597 DOI: 10.1245/aso.2006.08.011]
- 15 Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. *Pancreas* 2010; **39**: 458-462 [PMID: 19924019 DOI: 10.1097/MPA.0b013e3181bd6489]
- 16 Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K. Pancreatic Cancer Registry in Japan: 20 years of experience. *Pancreas* 2004; **28**: 219-230 [PMID: 15084961 DOI: 10.1097/00006676-200404000-00002]
- 17 Saka B, Balci S, Basturk O, Bagci P, Postlewait LM, Maithel S, Knight J, El-Rayes B, Kooby D, Sarmiento J, Muraki T, Oliva I, Bandyopadhyay S, Akkas G, Goodman M, Reid MD, Krasinskas A, Everett R, Adsay V. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤ 2 , pT2: ≥ 2 & ≤ 4 , pT3: ≥ 4 cm) is More Valid and Clinically Relevant. *Ann Surg Oncol* 2016; **23**: 2010-2018 [PMID: 26832882 DOI: 10.1245/s10434-016-5093-7]
- 18 Ling Q, Xu X, Zheng SS, Kalthoff H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. *Hepatobiliary Pancreat Dis Int* 2013; **12**: 480-487 [PMID: 24103277 DOI: 10.1016/s1499-3872(13)60076-4]
- 19 Khashab MA, Shin EJ, Amateau S, Canto MI, Hruban RH, Fishman EK, Cameron JL, Edil BH, Wolfgang CL, Schulick RD, Giday S. Tumor size and location correlate with behavior of pancreatic serous cystic neoplasms. *Am J Gastroenterol* 2011; **106**: 1521-1526 [PMID: 21468008 DOI: 10.1038/ajg.2011.117]
- 20 Park J, Lee KT, Jang TH, Seo YW, Lee KH, Lee JK, Jang KT, Heo JS, Choi SH, Choi DW, Rhee JC. Risk factors associated with the postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas. *Pancreas* 2011; **40**: 46-51 [PMID: 21160369 DOI: 10.1097/MPA.0b013e3181f66b74]
- 21 Oh TG, Chung MJ, Park JY, Bang SM, Park SW, Chung JB, Song SY. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. *Yonsei*

Med J 2012; **53**: 944-951 [PMID: 22869477 DOI: 10.3349/ymj.2012.53.5.944]

- 22 **Hauser CA**, Stockler MR, Tattersall MH. Prognostic factors in

patients with recently diagnosed incurable cancer: a systematic review. *Support Care Cancer* 2006; **14**: 999-1011 [PMID: 16708213 DOI: 10.1007/s00520-006-0079-9]

P- Reviewer: Bramhall S, Peng SY **S- Editor:** Gong ZM
L- Editor: Wang TQ **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045